Skip to main content
Top
Published in: Diabetologia 6/2006

01-06-2006 | Article

Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity

Authors: D. Boey, S. Lin, T. Karl, P. Baldock, N. Lee, R. Enriquez, M. Couzens, K. Slack, R. Dallmann, A. Sainsbury, H. Herzog

Published in: Diabetologia | Issue 6/2006

Login to get access

Abstract

Aims/hypothesis

Obese people exhibit reduced circulating peptide YY (PYY) levels, but it is unclear whether this is a consequence or cause of obesity. We therefore investigated the effect of Pyy ablation on energy homeostasis.

Methods

Body composition, i.p. glucose tolerance, food intake and hypothalamic neuropeptide expression were determined in Pyy knock-out and wild-type mice on a normal or high-fat diet.

Results

Pyy knock-out significantly increased bodyweight and increased fat mass by 50% in aged females on a normal diet. Male chow-fed Pyy / mice were resistant to obesity but became significantly fatter and glucose-intolerant compared with wild-types when fed a high-fat diet. Pyy knock-out animals exhibited significantly elevated fasting or glucose-stimulated serum insulin concentrations vs wild-types, with no increase in basal or fasting-induced food intake. Pyy knock-out decreased or had no effect on neuropeptide Y expression in the arcuate nucleus of the hypothalamus, and significantly increased proopiomelanocortin expression in this region. Male but not female knock-outs exhibited significantly increased growth hormone-releasing hormone expression in the ventromedial hypothalamus and significantly elevated serum IGF-I and testosterone levels. This sex difference in activation of the hypothalamo–pituitary somatotrophic axis by Pyy ablation may contribute to the resistance of chow-fed male knock-outs to late-onset obesity.

Conclusions/interpretation

PYY signalling is important in the regulation of energy balance and glucose homeostasis, possibly via regulation of insulin release. Therefore reduced PYY levels may predispose to the development of obesity, particularly with ageing or under conditions of high-fat feeding.
Literature
1.
go back to reference Larhammar D (1996) Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 62:1–11PubMedCrossRef Larhammar D (1996) Evolution of neuropeptide Y, peptide YY and pancreatic polypeptide. Regul Pept 62:1–11PubMedCrossRef
2.
go back to reference Herzog H (2003) Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur J Pharmacol 480:21–29PubMedCrossRef Herzog H (2003) Neuropeptide Y and energy homeostasis: insights from Y receptor knockout models. Eur J Pharmacol 480:21–29PubMedCrossRef
3.
go back to reference Pieribone VA, Brodin L, Friberg K et al (1992) Differential expression of mRNAs for neuropeptide Y-related peptides in rat nervous tissues: possible evolutionary conservation. J Neurosci 12:3361–3371PubMed Pieribone VA, Brodin L, Friberg K et al (1992) Differential expression of mRNAs for neuropeptide Y-related peptides in rat nervous tissues: possible evolutionary conservation. J Neurosci 12:3361–3371PubMed
4.
go back to reference Lundberg JM, Terenius L, Hökfelt T, Tatemoto K (1984) Comparative immunohistochemical and biochemical analysis of pancreatic polypeptide-like peptides with special reference to presence of neuropeptide Y in central and peripheral neurons. J Neurosci 4:2376–2386PubMed Lundberg JM, Terenius L, Hökfelt T, Tatemoto K (1984) Comparative immunohistochemical and biochemical analysis of pancreatic polypeptide-like peptides with special reference to presence of neuropeptide Y in central and peripheral neurons. J Neurosci 4:2376–2386PubMed
5.
6.
go back to reference Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89:1070–1077PubMed
7.
go back to reference Onaga T, Zabielski R, Kato S (2002) Multiple regulation of peptide YY secretion in the digestive tract. Peptides 23:279–290PubMedCrossRef Onaga T, Zabielski R, Kato S (2002) Multiple regulation of peptide YY secretion in the digestive tract. Peptides 23:279–290PubMedCrossRef
8.
go back to reference Chelikani PK, Haver AC, Reidelberger RD (2005) Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146:879–888PubMedCrossRef Chelikani PK, Haver AC, Reidelberger RD (2005) Intravenous infusion of peptide YY(3-36) potently inhibits food intake in rats. Endocrinology 146:879–888PubMedCrossRef
9.
go back to reference Riediger T, Bothe C, Becskei C, Lutz TA (2004) Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology 79:317–326PubMedCrossRef Riediger T, Bothe C, Becskei C, Lutz TA (2004) Peptide YY directly inhibits ghrelin-activated neurons of the arcuate nucleus and reverses fasting-induced c-Fos expression. Neuroendocrinology 79:317–326PubMedCrossRef
10.
go back to reference Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef Batterham RL, Cowley MA, Small CJ et al (2002) Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418:650–654PubMedCrossRef
11.
go back to reference Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR Jr (2004) Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology 145:4967–4975PubMedCrossRef Adams SH, Won WB, Schonhoff SE, Leiter AB, Paterniti JR Jr (2004) Effects of peptide YY[3-36] on short-term food intake in mice are not affected by prevailing plasma ghrelin levels. Endocrinology 145:4967–4975PubMedCrossRef
12.
go back to reference Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O’Rahilly S (2003) Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311:915–919PubMedCrossRef Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL, O’Rahilly S (2003) Acute effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the mouse. Biochem Biophys Res Commun 311:915–919PubMedCrossRef
13.
go back to reference Halatchev IG, Ellacott KL, Fan W, Cone RD (2004) Peptide YY3-36 inhibits food intake in mice through a melanocortin-4-receptor-independent mechanism. Endocrinology 145:2585–2590PubMedCrossRef Halatchev IG, Ellacott KL, Fan W, Cone RD (2004) Peptide YY3-36 inhibits food intake in mice through a melanocortin-4-receptor-independent mechanism. Endocrinology 145:2585–2590PubMedCrossRef
14.
go back to reference Pittner R, Moore C, Bhavsar S et al (2004) Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28:963–971PubMedCrossRef Pittner R, Moore C, Bhavsar S et al (2004) Effects of PYY[3-36] in rodent models of diabetes and obesity. Int J Obes Relat Metab Disord 28:963–971PubMedCrossRef
15.
go back to reference Tschop M, Castaneda TR, Joost HG et al (2004) Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430: 1 p following 165; discussion 2 pp following 165 Tschop M, Castaneda TR, Joost HG et al (2004) Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430: 1 p following 165; discussion 2 pp following 165
16.
go back to reference Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M (1998) Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci USA 95:15659–15664PubMedCrossRef Kushi A, Sasai H, Koizumi H, Takeda N, Yokoyama M, Nakamura M (1998) Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci USA 95:15659–15664PubMedCrossRef
17.
go back to reference Molero JC, Jensen TE, Withers PC et al (2004) c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action. J Clin Invest 114:1326–1333PubMed Molero JC, Jensen TE, Withers PC et al (2004) c-Cbl-deficient mice have reduced adiposity, higher energy expenditure, and improved peripheral insulin action. J Clin Invest 114:1326–1333PubMed
18.
go back to reference Hoentjen F, Hopman WP, Jansen JB (2001) Effect of circulating peptide YY on gallbladder emptying in humans. Scand J Gastroenterol 36:1086–1091PubMedCrossRef Hoentjen F, Hopman WP, Jansen JB (2001) Effect of circulating peptide YY on gallbladder emptying in humans. Scand J Gastroenterol 36:1086–1091PubMedCrossRef
19.
go back to reference Tatemoto K (1982) Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 79:2514–2518PubMedCrossRef Tatemoto K (1982) Isolation and characterization of peptide YY (PYY), a candidate gut hormone that inhibits pancreatic exocrine secretion. Proc Natl Acad Sci USA 79:2514–2518PubMedCrossRef
20.
go back to reference Bottcher G, Ahren B, Lundquist I, Sundler F (1989) Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas 4:282–288PubMedCrossRef Bottcher G, Ahren B, Lundquist I, Sundler F (1989) Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas 4:282–288PubMedCrossRef
21.
go back to reference Karlsson S, Ahrén B (1996) A role for islet peptide YY in the regulation of insulin secretion. Acta Physiol Scand 157:305–306PubMedCrossRef Karlsson S, Ahrén B (1996) A role for islet peptide YY in the regulation of insulin secretion. Acta Physiol Scand 157:305–306PubMedCrossRef
22.
go back to reference van den Hoek AM, Heijboer AC, Corssmit EPM et al (2004) PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53:1949–1952PubMedCrossRef van den Hoek AM, Heijboer AC, Corssmit EPM et al (2004) PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat diet. Diabetes 53:1949–1952PubMedCrossRef
23.
go back to reference Assimacopoulos-Jeannet F, Jeanrenaud B (1976) The hormonal and metabolic basis of experimental obesity. Clin Endocrinol Metab 5:337–365PubMedCrossRef Assimacopoulos-Jeannet F, Jeanrenaud B (1976) The hormonal and metabolic basis of experimental obesity. Clin Endocrinol Metab 5:337–365PubMedCrossRef
24.
go back to reference Standridge M, Alemzadeh R, Zemel M, Koontz J, Moustaid-Moussa N (2000) Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats. FASEB J 14:455–460PubMed Standridge M, Alemzadeh R, Zemel M, Koontz J, Moustaid-Moussa N (2000) Diazoxide down-regulates leptin and lipid metabolizing enzymes in adipose tissue of Zucker rats. FASEB J 14:455–460PubMed
25.
go back to reference Furuse M, Mabayo RT, Okumura J (1997) Effects of dietary cholestyramine on the utilisation of diets containing medium or long chain triacylglycerols by chicks. Br Poult Sci 38:436–438PubMedCrossRef Furuse M, Mabayo RT, Okumura J (1997) Effects of dietary cholestyramine on the utilisation of diets containing medium or long chain triacylglycerols by chicks. Br Poult Sci 38:436–438PubMedCrossRef
26.
go back to reference Sainsbury A, Schwarzer C, Couzens M et al (2002) Important role of hypothalamic Y2 receptors in bodyweight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA 99:8938–8943PubMedCrossRef Sainsbury A, Schwarzer C, Couzens M et al (2002) Important role of hypothalamic Y2 receptors in bodyweight regulation revealed in conditional knockout mice. Proc Natl Acad Sci USA 99:8938–8943PubMedCrossRef
27.
go back to reference West DB, Boozer CN, Moody DL (1992) Dietary obesity in nine inbred mouse strains. Am J Physiol 262:R1025–R1032PubMed West DB, Boozer CN, Moody DL (1992) Dietary obesity in nine inbred mouse strains. Am J Physiol 262:R1025–R1032PubMed
28.
go back to reference Mudali S, Dobs AS (2004) Effects of testosterone on body composition of the aging male. Mech Ageing Dev 125:297–304PubMedCrossRef Mudali S, Dobs AS (2004) Effects of testosterone on body composition of the aging male. Mech Ageing Dev 125:297–304PubMedCrossRef
29.
go back to reference al-Adsani H, Hoffer LJ, Silva JE (1997) Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 82:1118–1125PubMedCrossRef al-Adsani H, Hoffer LJ, Silva JE (1997) Resting energy expenditure is sensitive to small dose changes in patients on chronic thyroid hormone replacement. J Clin Endocrinol Metab 82:1118–1125PubMedCrossRef
30.
go back to reference Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML (1996) Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology 137:3–12PubMedCrossRef Pierroz DD, Catzeflis C, Aebi AC, Rivier JE, Aubert ML (1996) Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology 137:3–12PubMedCrossRef
31.
go back to reference Cho YR, Kim CW (2004) Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochem Biophys Res Commun 314:773–780PubMedCrossRef Cho YR, Kim CW (2004) Neuropeptide Y promotes beta-cell replication via extracellular signal-regulated kinase activation. Biochem Biophys Res Commun 314:773–780PubMedCrossRef
32.
go back to reference Morgan DG, Kulkarni RN, Hurley JD et al (1998) Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 41:1482–1491PubMedCrossRef Morgan DG, Kulkarni RN, Hurley JD et al (1998) Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 41:1482–1491PubMedCrossRef
33.
go back to reference Chen CH, Rogers RC (1997) Peptide YY and the Y2 agonist PYY-(13-36) inhibit neurons of the dorsal motor nucleus of the vagus. Am J Physiol 273:R213–R218PubMed Chen CH, Rogers RC (1997) Peptide YY and the Y2 agonist PYY-(13-36) inhibit neurons of the dorsal motor nucleus of the vagus. Am J Physiol 273:R213–R218PubMed
34.
go back to reference Havel PJ, Hahn TM, Sindelar DK et al (2000) Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 49:244–252PubMedCrossRef Havel PJ, Hahn TM, Sindelar DK et al (2000) Effects of streptozotocin-induced diabetes and insulin treatment on the hypothalamic melanocortin system and muscle uncoupling protein 3 expression in rats. Diabetes 49:244–252PubMedCrossRef
35.
go back to reference Ho KK, O’Sullivan AJ, Hoffman DM (1996) Metabolic actions of growth hormone in man. Endocr J 43:S57–S63PubMedCrossRef Ho KK, O’Sullivan AJ, Hoffman DM (1996) Metabolic actions of growth hormone in man. Endocr J 43:S57–S63PubMedCrossRef
36.
go back to reference Schonhoff SE, Baggio L, Ratineau C et al (2005) Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol 25:4189–4199PubMedCrossRef Schonhoff SE, Baggio L, Ratineau C et al (2005) Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol 25:4189–4199PubMedCrossRef
37.
go back to reference Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941–948PubMedCrossRef Batterham RL, Cohen MA, Ellis SM et al (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941–948PubMedCrossRef
Metadata
Title
Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity
Authors
D. Boey
S. Lin
T. Karl
P. Baldock
N. Lee
R. Enriquez
M. Couzens
K. Slack
R. Dallmann
A. Sainsbury
H. Herzog
Publication date
01-06-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0237-0

Other articles of this Issue 6/2006

Diabetologia 6/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.